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Introduction 
 
Neuropathic pain (NP) is a major disability in several neurological disorders with 
peripheral or central nervous system involvement, such as peripheral neuropathy, 
spinal cord lesions, stroke, or multiple sclerosis.  
Pain is a complex experience, strongly modulated by cognitive and educational 
influences, and understanding nociceptive function or dysfunction is a hard task for 
all pain specialists.  
NP remains a significant challenge to diagnose and treat effectively. 
Neuropathic pain is reported as neurological disorder with a high prevalence ranged 
from 3.3% to 8.2% (Bouhassira 2008, Gustorff 2008, Torrance 2006), is an important 
public health problem.  
 
Neuropathic pain definition 
 
Neuropathic pain has been recently redefined by the Assessment Committee of the 
Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association 
for the Study of Pain (IASP) as : “pain which arises directly from a lesion or disease 
affecting the somatosensory pathways” (NeuPSIG, Treede 2008). The current IASP 
definition is: ‘‘pain initiated or caused by a primary lesion or dysfunction of the 
nervous system” (Merskey 1997). 
In particular, the “new” definition proposed by NeuPSIG replaces the substantive 
‘‘dysfunction” by the substantive ‘‘disease” to distinguish neuropathic pain from 
that kind of pain caused by neuroplastic changes in response to strong nociceptive 
stimulation (Geber et al., 2009). 
Moreover, the term ‘‘nervous system” is replaced by the term ‘‘somatosensory 
system” to distinguish neuropathic pain from pain caused by lesions in other parts 
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of the nervous system, i.e. pain associated with muscular spasticity rising from 
lesions of central motor pathways. 
This redefinition has strong practical diagnostic implications.  First of all the 
diagnosis of NP requires evidence for a lesion affecting a neuroanatomically 
identifiable part of the peripheral or central somatosensory system, which is 
consistent with the distribution of the pain (Treede, 2008; Haanpaa 2010). The 
grading of certainty for the presence of NP consists of  
- Definite NP: all (1-4); 
- Probable NP: 1 and 2, plus either 3 or 4; 
- Possible NP: 1 and 2, without confirmatory evidence from 3 or 4. 
The levels ‘‘definite’’ and ‘‘probable’’ indicate that the presence of this condition has 
been established. The level ‘‘possible’’ indicates that the presence of NP has not yet 
been established. Notably, if a patient does not fulfil the criteria for any of these 
three levels, it is considered unlikely to have NP (Treede, 2008; Haanpaa 2011). 
As direct consequence of this a specific and detailed clinical evaluation and 
confirmatory testing are required to reach the NP diagnosis. The challenge is to 
differentiate neuropathic pain from other types of pain and to diagnose the lesion 
or disease causing the pain. Standard neurophysiological tests, such as nerve 
conduction studies and somatosensory evoked potentials, are useful to 
demonstrate, locate and quantify damage along the peripheral and central 
pathways, but they do not assess the function of nociceptive (C and A-delta) 
pathways (Cruccu 2004, Cruccu 2010, Haanpaa 2011). 
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Neuropathic pain syndrome diagnosis 
 
We may distinguish the diagnostic tools into four major group : 1- pain 
questionnaires and scales ; 2- quantitative sensory testing:  a multimodal approach 
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able to quantify the sensory thresholds using graded stimuli ; 3- extensive 
neuroalgological bedside evaluation, related to either the clinician experience and 
the collaboration of the patient ; 4- laboratory or instrumentals tests that quantified 
objective responses as confirmatory tests for NP diagnosis. 
 
Screening tools: pain scales and questionnaries 
 
In recent years, several scales and questionnaries based on verbal pain description 
have been developed and validated in NP. First of all, the Leeds assessment of 
neuropathic symptoms and signs (LANSS) contains 5 symptom items and 2 clinical 
examination items (Bennet, 2001; Bennet, 2005). A score of 12 or more out of a 
possible 24 suggests the presence of NP. Moreover a self-report tool, the S-LANSS 
has also been validated (Bennet, 2005). 
The neuropathic pain questionnaire (NPQ) consists of 12 items that include 10 
related to sensations or sensory responses (Krause, 2003). It was reported to be 
power to discriminate between NP and non-NP (Haanpaa, 2011). 
Douleur neuropathique en 4 questions (DN4) consists of 7 items related to 
symptoms and 3 related to clinical examination (Bouhassira, 2005). The DN4 is easy 
to score and a total score of 4 out of 10 or higher suggests possible NP. The first 7 
items can be used as a self-report questionnaire with similar results (Bouhassira, 
2005). Untill now, the DN4 has been used in large epidemiological studies to 
estimate the prevalence of NP both in the general population and specific NP 
disorders as  diabetic neuropathy. 
The painDETECT was developed and validated in German and includes a self-report 
questionnaire with 9 items (Freynhagen, 2006). There are 7 sensory descriptor items 
and 2 items relating to the spatial and temporal characteristics of the specific pain 
pattern. It is available in German and English, has been translated in 22 languages 
(not yet validated in Italian language).  
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ID-Pain consists of 5 sensory descriptor items and 1 item relating to pain localization 
in the joints to identify nociceptive pain; it also does not require a clinical 
examination (Portenoy, 2006). A recommended cut- off score of above 3 points 
suggestes the presence of NP. 
The neuropathic pain symptom inventory (NPSI) contains 10 descriptors grouped 
into 5 distinct pain qualities (burning, paroxysmal, deep, evoked, paresthesia) and 2 
temporal items which assess pain duration and the number of pain paroxysms. The 
originally validated French NPSI has been translated and linguistically validated in 
about 50 other languages, moreover, its conceptual adequacy has been confirmed 
in several languages  and it has been revalidated in Italian (Padua et al., 2009).  
 
Its structure makes it suitable to represent different aspects of NP that may have 
distinct pathophysiological mechanisms and may correlate to functional and 
neurophysiological data. For these reasons we choose this questionnaires for our 
research projects.  
 
Clinical presentation QST, EPs, skin biopsy 
 
Quantitative Sensory Testing (QST) quantifies the different modality of sensory 
perception in response to external graduate stimuli of controlled intensity. The 
detection of sensory or painful threshold can be used in clinic along with bedside 
testing to document the sensory profile.  
Conventional neurophysiological studies such as nerve conduction studies (NCS), 
somatosensory-evoked potentials (SEPs), can identify and quantify a lesion along 
the peripheral or central sensory pathways, but they do not assess the nociceptive 
pathway integrity. For many years the neurophysiological diagnosis of nociceptive 
lesion has been a challenge. The introduction of laser evoked potential using a laser 
stimulus that selectively elicits the free nerve endings (Ad and C) in the superficial 
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skin layers has provided a tool to addess it.  In painful peripheral neuropaties are 
typically involved the small fibres C and A delta. To assessed their damage also in 
the early phases of neuropathy the quantification of intraepidermal and dermal 
nerve fibers using skin biopsy is a relatively simple, mininvasive and reliable method. 
 
Treatment of NP 
 
Pharmacological treatment of NP 
 
The management of NP is challenging because the response to most drugs remains 
unpredictable or poorly despite attempts to develop a more rationale therapeutic 
approach (Finnerup, 2006, Baron 2006). Recently the European Federation of 
Neurological Societies (EFNS) produced the revision of guidelines on 
pharmacological treatment of NP (Attal, 2010). 
Tricyclic antidepressants (TCA) (25– 150 mg/day) and anticonvulsants as gabapentin 
(1200–3600 mg/day) and pregabalin (150–600 mg/day) are recommended as the 
first line of treatment for various NP conditions (except for trigeminal neuralgia), 
while lidocaine plasters (up to 3 plasters/day) first line in postherpetic neuralgia 
PHN. 
In painful diabetic polyneuropathies SNRI (duloxetine 60–120 mg/ day, venlafaxine 
150–225 mg/day) as first line has been recommended.  
Second-line treatments include other medications such as tramadol and in PHN 
capsaicin cream. Oxicodon and other strong opioids are recommended as 
second/third line because of potential risk for abuse on long-term use. Finally 
Cannabinoids have a level A in MS and peripheral NPand are proposed for refractory 
cases. 
Combination therapy is still not well established in NP however is recommended for 
patients who show partial response to drugs administered alone (level A for 
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gabapentin combined with opioids or TCA) (Attal, 2010). 
Peripheral neuromodulation in treatment of NP 
 
Peripheral nerve stimulation (PNS) is a neuromodulation technique in which 
electrical current is applied to the peripheral nerves to improve chronic pain. It is 
first described in 1967, then a variety of techniques have since been developed. In 
the 1970s PNS was seldom performed because the high morbidity and poor 
outcomes. The reasons suggested ranged from poor patients selection and 
limitations related to inadequate devices. 
However, growing evidences assessed that PNS is effective in particular NP 
syndromes characterized by peripheral nerve lesions or irritation with pain or 
positive phenomena with a localized peripheral nerve distribution. The most 
common painful syndrome treated with PNS are trigeminal branch stimulation, the 
occipital nerve stimulation (Weiner 1999)  and subcutaneous peripheral nerve 
stimulation also known as sPNS. 
Cranial nerves PNS is widely used also for treatment of chronic painful syndrome like 
headache including migraine (Popeney, 2003), TACs and cluster headache (Broggi, 
2009; Goadsby, 2007). Less commonly PNS is applied at trunk peripheral nerve 
disorders, tibial neuralgia, inguinal neuropathy, meralgia paresthesica. 
The Patients selection has to be quite selective, and the screening work up includes 
general   clinical and serological evaluation to assess the comorbidity, psychological 
screening to rule out psychological amplifiers of pain or other confounding 
conditions (severe depression, psychosis, behavioural disorders, drugs and 
substance abuse). Usually the use of local anesthetic  injection along the peripheral 
nerve is thought as informative pre-test as screening tool to confirm the appropriacy 
of PNS. 
The neurological, neurophysiological and or neuroradiological examination could 
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help in diagnosis and confirm the presence of definite neuropathic pain. A trial 
period with temporary electrodes generally lasts 7-14 days. If patients experienced a 
sufficient pain relief (usually more then 50% from the baseline), a permanent 
system is implanted.  
Intraoperative testing, when performed, confirms that stimulation paresthesias are 
in the right position able to cover the painful skin area. 
Permanent leas are connected to an implantable pulse generator (IPG). The final 
position of IPG depends from the nerve electrocateters, i.e. the subclavicular area is 
used for cranial nerve electrodes, while the thigh and upper arm is choose for lower 
or upper harm electrocatheters.  
Currently PNS procedures are performed using devices not specifically approved for 
this application, i.e. devices approved for spinal cord stimulation.  
Most recently subcutaneous peripheral nerve stimulation (S-PNS) has been 
introduced. In S-PNS  electrodes are placed directly in the subcutaneous space of 
the painful skin area.  
The electrodes is supposed to elicit the small subcutaneous nerve fiber and branch. 
This kind of stimulation is used to treat pain condition with less defined pain 
distribution. Concerning the mechanism of action, it is still unclear. The gate control 
mechanism is the most reported, moreover for PNS another mechanisms is due 
from the periphery: in such NP conditions has been suggested a dysfunction of 
nociceptors with alteration of the local conductance activity, of the terminal 
chemistry and the efferent function of peripheral small fiber end terminals (Byers, 
2001). 
There are several emerging indications for S-PNS as Complex Regional Pain 
Syndromes (CRPS), axial neck pain, low back pain and failed back surgery syndrome. 
In Literature long term efficacy of PNS is rarely described and are often reported 
several sides effects and complication i.e. electrocatheters dislocation and 
infections. 
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Peripheral Nerve Stimulation of brachial plexus for treatment of chronic post 
traumatic Neuropathic Pain 
 
Background and aims 
 
Chronic peripheral neuropathic pain due to peripheral nerve injury often results in 
significant suffering and impaired quality of life. It is poorly responsive to drugs 
usually used for the treatment of neuropathic pain (NP) such as anticonvulsants and 
membrane stabilizers and opioids, even at high dosages. Therefore, an effective  
treatment for neuropathic pain still remains a major clinical challenge. 
Peripheral nerve stimulation (PNS) has been used by a small group of neurosurgeons 
for the treatment of chronic peripheral neuropathic pain since 1965. Although in 
Literature PNS was demonstrated to be quite successful on the short and middle  
term (Eisenberg 2004, Van Calenbergh 2009), PNS has never become a standard 
technique for treatment of NP syndrome. This may be due to technical difficulties  
with  paddle-type electrodes inserted around the peripheral nerve and to the risk of 
infections or electrodes dislocation. 
The mechanism by which PNS produces analgesia is still unclear.  
One of the possible mechanisms is based on the assumption that direct application 
of low-intensity high-frequency electrical current on to a peripheral nerve can elicit 
the A-beta myelinated fibers and produce analgesia  according to the “gate control” 
mechanism (Melzack and Wall, 1965). Then main mechanism proposed as key part 
of PNS is closely related to the brain function and the brain plasticity in particular 
(Stanton-Hicks, 2011). 
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Thus,  we hypothesized that the implantation of PNS leads directly on the nerve 
branch mainly involved in painful syndrome, proximally to the site of injury, may 
produce analgesia or significant  pain relief in patients with traumatic nerve injuries. 
For this purpose an  at least partially preserved pathway is required.  
In the present study, we  assessed the short and  middle-term outcome of PNS in a 
series of patients with peripheral post-traumatic neuropathic pain at the upper 
harm. The aim of the study was to evaluate pain relief in this selected group of 
patients due the direct stimulation of the nerves branches administered by means 
of lead inserted with a peculiar and innovative surgical technique.  
 
 
Patients and Methods 
 
Patients  
 
Patients affected by intractable pain due to peripheral nerve injuries and referred to 
our neurological unit for advanced pain treatment during the years 2007–2010 were 
considered for PNS.  
A detailed medical history and neurological examination were collected.  
Peripheral neuropathic pain was defined as chronic pain in an area of sensory 
abnormality corresponding to the nerve lesion and with an onset less than 6 months 
after the lesion, according to the gradying system proposed by the NeuPSIG 
guideline (Haanpaa 2011). 
Patients were carefully selected for PNS after an extensive baseline assessment. 
Therefore, we identify the following criteria for inclusion: (1) clear identification of 
an isolated injured nerve (i.e., selective branch of brachial plexus, median nerve, 
radial nerve) by means of clinical and electroneurographic and electromyographic 
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evaluation as the unique cause of pain; (2) complete although transient pain relief 
following a diagnostic nerve block with local anesthetics; (3) poor response (<50% of 
pain relief) to all other treatments, including drugs assumption, surgical treatment 
of the injuries site such as neurolytic procedures, neuroma resection, nerve grafting 
and transection; (4) absence of major psychiatric disorders, such as personality 
disorders or major depression,  as assessed by psychological examination using 
Minnesota Multiphasic Personality Inventory (MMPI); (5) signing of a written 
informed consent for the study and for surgical procedure.  
The study was single-centre, open-label  and received the institutional review board 
approval. 
 
Neurological and algological baseline examination  
 
All subjects underwent a complete neurological and algological examination of the 
upper and lower trunk, medial, lateral, and posterior cords of the brachial plexus 
and peripheral nerves, in order to assess the motor and sensory loss distribution and 
positive phenomena as following described. 
Superficial and pinprick sensations were examined in order to identify negative 
sensory signs (sensory loss) and positive sensory signs (evoked and spontaneous 
pain, paraesthesias). The neurological examination was performed using cotton 
gauze (light touch and dynamic mechanic allodynia test) and a brush, disposable 
safety needle (hypoalgesia, pinprick hyperalgesia, aftersensation test), repetitive 
pinprick (2Hz for 30 seconds) and glass vials filled with cold and hot water (thermal 
sensation, allodynia test, aftersensation test). Deep tendon reflexes were classified 
as normal, decreased (if present with reinforcement) or absent. All muscle groups of 
the upper harm were evaluated and muscle strength was graded using the Medical 
Research Council (MRC) score.  
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Intensity of spontaneous pain, allodynia including static mechanical (pressure), 
dynamic mechanical (brush), heat or cold (thermal) and hyperalgesia were graded 
using the NRS (0-10) scale. We used the following descriptors for quality of pain: 
throbbing, lancinating, unpredictable, lightning-like, sharp, shooting, aching, 
burning, scalding, pruritic (Galer and Jensen, 1997; NPSI 2009).  Pain attacks were 
described by intensity, duration, and frequency.  
We collected a picture for the pain on the skin and detailed pain map and sensory 
abnormalities distribution on a body chart. 
Finally the clinical evaluation was completed with upper harm examination in order 
to rule out of intrinsic joint disease, acromioclavicular pathology and in patients with 
lower brachial plexus involvement the elevated arm stress test (Roos, 1966) was 
performed in order to relieve thoracic outlet syndrome (Robert J. Schwartzman, MD, 
and John R. Grothusen, PhD). 
 
Quantitative Sensory Testing 
Thresholds for cold and warm sensation (CS, WS) and cold and heat pain (CP, HP) 
were obtained bilaterally on the thenar and hypothenar eminences, and on other 
sites according with the neuroanatomical distribution of pain and negative signs, 
with a 30x30mm thermode of the TSA-II Neuro Sensory Analyzer (Medoc, Israel). 
Method of limits has been performed. Each test was repeated four times for each 
side and the perceived threshold was defined as the average of peak temperatures. 
Subjects were instructed to push the response button, which recorded the 
temperature and reset the thermode back to baseline, as soon as they detected a 
change in temperature for CS and WS, or only if the sensation changed from cold or 
hot to painful sensation.  
Surgical Procedure 
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Surgical procedures were performed at the General Hospital of Mestre-Venice  
between 2007 and 2010. All implantations were performed under general 
anesthesia and under strict sterile conditions by one surgeon (G.S.). The nerves 
selected for surgery were exposed proximal to the site of injury using the tecnique 
of brachial plexus exposition by the axillary approach. Patients were supine with the 
upper harm abducted by 90°, all the nerve and vascular structure are  exposed, 
identified and classified as shown in figure 1. 
Two On-Point leads (Medtronic Inc., Minneapolis) were used for the stimulation of 
the radial or/and the median nerve respectively. Each lead has 4 platinum-iridium 
electrodes on a silicone-rubber mesh. During the surgical procedure, the leads were 
placed upon the sensitive portion of the nerve according to the Sunderland’s 
scheme (Sunderland, 1978) about 4cm far from the rising nerve, and carefully 
anchored by means of lead paddle mesh with absorbable sutures in order to avoid 
nerves compression. This technical solution allows the nerves protection by the 
surrounding fibrosis and provides stability of the overall system. 
If the patient had motor function preserved at baseline, a stimulation trial was 
carried out by mean of a quadripolar lead in order to confirm the position near to  
sensory fibers and not near to motor fibers. 
The electrodes were tunneled under the skin, making several loop in order to 
minimize traction or dislocation with the upper harm movement, and then 
connected the temporary extensions. During the trial period an external stimulation 
(ENS, Medtronic Inc, Minneapolis) was used. 
After the trial period, temporary extensions were removed and replaced by 
permanent extensions then connected to an implantable pulse generator (IPG, 
mod.Prime advanced, Medtronic Inc., Minneapolis) that was secured in the 
subclavicular subcutaneous pocket.  
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During the first trial after about 24 h from the procedure, the pulse rate, width, and 
voltage that produced the best response were selected. All patients has a continuos 
stimulation set.  
Daily pain evaluation and scales  
Patients were requested to evaluate their pain intensity with the use of a 11-points 
Likart scales (NRS), where “0” means “no pain” and “10” means “the worst 
imaginable pain”. Additionally, they were asked to describe their pain with the use 
of the Pain Questionnaire (Galer and Jensen, 1997; NPSI 2009).  
 
Pain and clinical follow-up evaluation 
Patients were assessed during scheduled follow-up visits for efficacy evaluations 
after 1 week, 1 month and every 6 months thereafter for the next 2 years from the 
IPG implantation. QST  was assessed at baseline, 1 month and 12 or 24 months with 
stimulation turned ON. However, patients who lived far away were followed up by 
telephone calls 6 and 18 months after the IPG implantation to obtain information  
on long-term pain intensity and analgesics consumption .  
Patients were asked to fill out the pain questionnaire and clinical evaluation at 
follow-up evaluation in two conditions: with the stimulator switched off (“OFF”) and 
stimulator switched on (“ON”). The stimulator was switched “ON” or “OFF” by a 
technician that randomized the order of the 2 condition. The neurologist (G.D.) that 
performed the clinical and QST evaluation and the patient were blinded to the 
condition of the stimulator. In all the patients the peripheral nerve stimulation was 
at low intensity in order to obtain sufficient pain relief without paresthesiae 
sensation. In this way the patient was blinded to the Stimulator condition (“ON” or 
“OFF”).  
A sufficient time interval, based on the clinical history, was left between the 2 
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assessment periods, to minimize potential carry-over effects of PNS. 
 
Statistics 
A 2-tailed t test was used to compare NRS values and analgesic consumption prior to 
surgery and during the follow-up. Results at the P < 0.05 level were regarded as 
statistically significant.  
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Results 
 
Patients. 
We identify 7 patients (all men) fulfilling the inclusion criteria and suitable for PNS. 
All the 7 patients had a  post-traumatic lesion of brachial plexus or distal peripheral 
nerve complaining severe intractable pain characterized by positive phenomena like 
allodynia, paradoxical pain and ongoing pain. The clinical data are reported in table 
1 and 2. In 4 patients a traumatic peripheral nerve lesion occurred, while in 3 a 
traumatic brachial plexus postganglionic injury caused the peripheral NP syndrome. 
Their age ranged from 17 to 68 years, with a median age of 46y.o. Pain duration 
prior to PNS range from 19 months to 31 years. The mean baseline NRS was 9/10, 
indicating moderate to severe mean pain intensity before surgery. The patients 
described the painful syndrome with several qualities like cutting sensation, burning 
sensation, constriction with impressive positive phenomena like electric shock after 
light touch or movement, several times every day. From the history all patients had 
previously received neurosurgery neurosurgical treatments including neurolysis. 
Therefore all patients of them underwent conventional medications  (analgesics, 
antidepressants, anticonvulsants) (see table 2) and repeated nerve blocks. None of 
the patients met the research diagnostic criteria for complex regional pain 
syndrome II (CRPS II) (Harden, 2006). 
The follow-up evaluation 
The follow-up period was ranged from 18 months to–4 years, with a median value of  
years. The results based on pain relief were classified as good in all patients. The 
stimulation parameters of PNS were similar in all patients: with a 50Hz frequency of 
50Hz, a 250usec of pulse width of 250µsec, and an amplitude ranging from 0.15 to-
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0.30 V of Amplitude. 
Overall, pain intensity dropped decrease from a NRS of  9±1.15  before surgery to 
2.14±1.57 at 6-month of follow-up and to 2.57±1.13  at 12-months of follow-up (P < 
0.001). No complications like infections, dislocation or electrodes dislocations or 
migrations occurred in none patient. In two patients a sudden pain sensation were 
reported and we observed in both a transient PNS dysfunction due from to 
magnetic interference. Patients shown peripheral (hand) oedema and skin 
discoloration similar to that observed in CRPS, with cold skin cyanosis without sweat 
dysfunction.  
QST battery at baseline and at follow-up 
Thermal tresholds were abnormal in all patients according to the neuroanatomical 
distribution of negative signs as expected by the sensory clinical evaluation, in 
particular we found higher cold and warm sensation in selective skin area. In 6 of 7 
patients at baseline we found positive phenomena characterized by cold or warm 
allodynia and in 5 wrong painful sensation after cold and warm stimuli into not 
painful range. The abnormal painful sensation was reported as an electrick shock or 
burning sensation with wide skin area distribution, higher then expected by the 
nerve injuried distribution suggesting a peripheral or central hypersensitivity 
phenomena. We reported an example of sensory profile in figure 1a. 
After 6 months at the follow-up evaluation thermal QST evaluation showed 
unchanged negative signs pattern and attenuation or complete resolution of 
positive phenomena.  
At follow-up evaluation when the neuromodulation was blinded switch OFF after a 
mean ranged from 22 seconds to 54 seconds, they felt pain with NRS ranged from 8 
to 10, with the same characteristics collected at the baseline pre – implant 
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evaluation before the trial test.   During the stimulation “OFF” period, In four of 
seven patients we observed in this trial skin discoloration with cyanosis. During a 
trial of 1 h we observed a mild distal oedema. After the blinded turned “ON” of PNS 
the painful sensation disappeared with complete restore of pain relief in about 20-
30 seconds and after a mean of 1 h all the autonomic signs disappeared. 
 
Discussion  
Peripheral nerve stimulation (PNS) is a neuromodulation technique in which 
electrical current is applied to the peripheral nerves to improve chronic pain. It is 
first described in 1967, afterwards a variety of techniques have since been 
developed. In the 1970s PNS was seldom performed because the high morbidity and 
poor outcomes related to poor patients selection and technical limitations for 
inadequate devices. However, growing evidences suggested that PNS is effective in 
particular NP syndromes characterized by peripheral nerve lesions or irritation with 
pain or positive phenomena with a localized peripheral nerve distribution (Weiner 
1999).   
In the present study we show a selected case series of patients complain severe 
neuropathic pain involving the upper arm with pain phenomena extremely 
consistent to a peripheral nerve distribution. This clinical picture is usually at high 
risk for non-responsiveness with others neuromodulation tecniques such as motor 
cortex stimulation or spinal cord stimulation. However, peripheral nerve stimulation 
through a percutaneous approach - in particular for upper and lower limb - has poor 
outcome for high incidence of morbidity, related to the movement and critical 
structures (i.e. tendons, nerves, vascular structures) in limited spaces.  
In Literature, the use of a prognostic nerve block prior to PNS has been suggested by 
several groups, and from common practice it is well accepted that failure to respond 
to a nerve block is a bad prognostic factor for PNS. For that reason, complete 
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although temporary pain relief following a diagnostic nerve block with local 
anesthetics was required as pre-test also in our screening evaluation. The use of  the 
local anesthetic injection may help us in order to confirm the selection of the nerve 
target, and to confirm the prevalent peripheral mechanisms at the basis of the pain 
syndrome. Then the carefully evaluation of positive and negative signs and QST 
battery as screening tools defined the sensory pattern. 
As reported also by other groups (Van Calenbergh, 2009) we observe that PNS did 
not modify neither heat or cold thresholds assessed by QST battery. Therefore the 
main finding for QST battery was the clear anti-allodynic or anti-hyperalgesic effect. 
In QST battery Z score profile the result is a reduction in positive phenomena with 
unchanged negative signs. The improving of positive phenomena is a direct effect of 
the PNS stimulation, while the negative signs in our patients are the consequence of 
the nerve lesion and PNS is obviously ineffective to improve a loss of peripheral 
nerve function like sensory sensation. However PNS can make a sort of noise in pain 
signals related to peripheral or central hypersensibilization,  producing anti-allodynic 
effect.  
The PNS is assessed to be a long-lasting  beneficial therapy and a follow-up of more 
than 15 years is reported. The double-blind control test with the two condition 
(STIM "ON"; STIM "OFF") confirm the efficacy of PNS in our patients. Conversely to 
SCS, the analgesic and anti-allodynic effect is easily reached in few minutes. Notably, 
we observed in some of our patients peripheral autonomic dysfunction like 
peripheral oedema or cyanosis with the PNS switch OFF, as collateral findings, 
suggesting peripheral mechanisms in axonal reflexes and vasogenic neurally 
mediated effects. 
The follow-up of a mean of 2 years confirms the long-lasting beneficial effect of SCS, 
nearly unchanged between visit 1 month to visit after 2 years. 
Finally, we assessed the usefulness of Thermal QST to detect the positive 
phenomena in our patient, with a sort of stereotypical and reliable QST pattern also 
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confirmed by several observations (data not shown), and above all for follow-up 
evaluation to clearly detect the antiallodynic effect of PNS. 
In conclusion, PNS can result in long-term pain relief in the majority of carefully 
selected patients and has a relatively low complication rate. It should therefore be 
considered as a reasonable treatment of patients suffering from otherwise 
intractable and isolated painful neuropathies. 
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Pain, referred sensations, in brachial plexus injury. 
 
Table 1 
Pain, referred sensations, in brachial plexus injury. 
 
Table 1 
 
Patient 
no. 
Gender, 
age 
(years) 
 
 
 
etiology 
 
Duratio
n of 
plexus 
or nerve 
lesion 
 
(yrs, 
mo) 
Suggested 
nerve 
lesion 
Dermatomes 
or nerve area 
with 
abnormal 
sensation 
 
Site of 
lesion 
Concommitant 
injury 
NRS 
(at baseline) 
Ongoing 
pain 
treatment 
1 M, 58 
Accident 
at work 
8 yrs 
Median, 
radial 
nerves 
Median, 
radial nerves 
Median and 
radial nerve 
lesion at 
third distal 
of forearm 
Partial 
Amputation of 
forearm 10 
TCA, 
pregabalin, 
opioid 
2 M, 68 
iatrogenic 19 mo 
Median 
nerve Median nerve 
Proximal site 
of Median 
nerve   8 
Pregabalin, 
opioid 
3 M, 42 
Accident 
at work 
4yrs 
Median, 
radial 
nerves 
Median, 
radial nerves 
 
Nerve injuri 
at phalaneal 
level 
Distal 
Amputation (II, 
III, IV fingers) 10 
Tramadol, 
gabapentin 
4 M, 47 
Accident 
at work 
3yrs 
Median 
nerve Median nerve 
 
C6 – C7 
lateral cord Amputation 7 
Paracetamol
, NSAID, 
opioid, 
gabapentin 
5 M, 54 
Motorcycl
e accident 
31yrs 
Median 
nerve Median nerve 
Severe injury 
at lateral 
cord    9  - 
6 M, 17 
Motorcycl
e accident 
32mo 
Median 
nerve Median nerve 
C6 – lateral 
cord 
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High dosage 
Opioid, 
Pregabalin, 
TCA 
7 M, 36 
Motorcycl
e accident 
14yrs 
Median 
nerve Median nerve 
(C5)-C6-C7-
C8 
postganglion   9 
Opioid, 
Pregabalin, 
TCA 
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i lesion 
 
 
 
 
Table 2 
 
  
Background 
pain 
Spontaneous pain paroxysms 
  
Evoked pain, NRS 
      
No. Of 
points w. 
Increased 
sensation 
No of 
points w. 
Referred 
sensation 
Patient 
no. 
Intensity, 
NRS 
Intensity, 
NRS 
Duration 
(s) Frequency Brush Pinprick 
Repetitive 
Pinprick Cold Warm 
1 10 7 15 4/day 10 8 5 5 8 24 5 
2 8 5 30 1/h 9 5 4 3 2 1 5 
3 10 10 10 1/h 10 1 6 6 9 13 0 
4 7 8 160 10/h 10 10 10 10 7 11 0 
5 9 9 5 1/month 7 7 8 5 8 16 2 
6 10 10 30-45 1/h 5 8 10 7 6 16 4 
7 9 5 2-3 3/day 6  6  5 5 6 0 0 
 
Clinical evaluation and neuroalgological pattern. 
 
 
 
 
Patient 
no. 
Intensity, 
NRS 
48h 6 12 18 24 30 36 42 
1 10 2 1 2 5 4 3 2 3 
2 8 0 2 2 3 2 2 2 0 
3 10 3 4 4 4 5 4 3 4 
4 7 1 1 2 2 2 1 2 - 
5 9 3 4 4 4 5 3 - - 
6 10 0 0 1 - - - - - 
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7 9 2 3 3 - - - - - 
 
 
 
 
Fig. 1 Mean NRS (0-10) at baseline and follow-up evaluation after PNS . 
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Fig.2 Brachial plexus exposition at the axillary cavum, external neurolysis, insertion of a 
quadripolar electrode. 
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Cold painful neuropathy a peculiar phenotype of neuropathic pain  
 
Introduction 
 
It is established that cold sensation is mediated by small myelinated A delta ®bres 
(Yarnitsky and Ochoa, 1991), while cold pain is probably mediated by the activation 
of both thinly myelinated cold-specific A delta fibres and unmyelinated C fibres 
(LaMotte and Thalhammer, 1982; Wasner, 2004). In particolar, using 
microneurographic recordings, C fibers activated by cold painful stimuli has been 
classify as polymodal nociceptors (Torebjork, 1974; Torebjork and Hallin, 1973). It is 
a common experience that in several pathological conditions like peripheral 
neuropathy, innocuous skin cooling can induce pain (Woolf and Mannion, 1999; 
Baron, 2000).  
The mechanisms of cold pain and cold positive phenomena such as cold 
hyperalgesia or allodynia are less understood than of burning pain.  It has been 
suggested a central mechanism characterized by a decrease in the inhibition 
normally exerted centrally by cold sensory channels on nociceptive channels (Craig 
and Bushnell, 1994; Craig et al., 1996), but peripheral mechanisms has been 
suggesteded (Wasner et al., 2004).  
In humans a simple model for studying cold hyperalgesia is the topical application of 
L-menthol (C10-H20O), that is a specific agonist of cold - sensitive nociceptor of the 
TRP channels family, TRPM8 expressed on A delta afferent and small diameter 
dorsal root gangia (DRG) neurons (McCoy et al., 2010).  TRPM8 is activated by by 
menthol and cooling, with an activation temperature ranged from 25 to 28°C. 
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Notably, at the DRG level TRPM8 is not co-expressed with the TRPV1, suggesting the 
cold-specificity of the TRPM8-positive A delta fibres (McKemy et al., 2002, Facer et 
al., 2008). Among the TRPM8 receptor, from the TRP channels family the TRPA1 
have been identified as cold-sensitive ion channels. TRPA1 is activated by potentially 
painfully cold temperature (below 15°C), and by a ranged of esogenous irritants 
such as mustard oil, cinnamaldehyde (CA), formalin, reactive oxygen species (Obata 
et al., 2005) and a variety of endogenous reactive compound related to pathological 
conditions, including hydrogen peroxide and 4-hydroxynonenal (4-HNE). These 
evidences suggest that TRPA1 may play a role in several pathological pain 
conditions. It is established that TRPA1 shares some pharmacological features with 
TRPM8, i.e. menthol clocks TRPA1 at high concentration (Karashima et al., 2007). In 
recent years several studies in experimental conditions in healthy humans try to 
clarify different pain syndromes (Wasner et al., 2004, NAmer et al., 2005, Tugnoli et 
al., 2007), however little is known about the mechanisms underlying the cold pain in 
peripheral neuropathic pain syndromes. 
In small fiber neuropathy only 1-2% of patients describe a peculiar pain condition 
characterized by cold pain and cold paroxysms (Verdugo and Ochoa et al., 1992; 
Devigili et al., 2008). Cold spontaneous pain and cold hyperalgesia are common 
symptoms in patients with painful neuropathy, however pain phenotypes and 
mechanisms underlying are still poorly understood.      
The aims of study was to characterize the distinct pattern of pain phenomena in 
patients with cold pain and to compare clinical features, neurophysiological and 
histological profile in order to understand the underlying pain mechanisms.  
 
Patients and Methods 
 
Study population. 
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We selected 9 patients with painful small fiber neuropathy (SFN) complaining cold 
pain (group 1, c-SFN) during a period from 2008 to 2010. Then we selected 10 
patients with the classical form of burning painful SFN (group 2, b-SFN), and a 
control group of 15 healthy subjects age and sex matched. All patients received the 
diagnosis of SFN assessed by history, clinical examination, skin biopsy and thermal 
thresholds QST.  We selected only patients with all these tests abnormal to make a 
diagnosis of definite SFN. A complete neuroalgological and neurological examination 
were performed. Patients underwent nerve conduction studies, and if necessary 
EMG studies and pain questionnaire (DN4 2004, NPSI 2009 and Neuropathic Pain 
Questionnary 1997). 
 
Experimental protocol 
Substances. 
We used as TRPM8-agonist a solution of L-menthol (40%) dissolved in 90% ethanol, 
and as TRPA-1 receptor agonist cinnamaldehyde (CA), while as placebo control for L-
menthol we used a solution of ethanol 90% and for CA a solution of acetone 
(CH3COCH3) that produces a similar smell. In different days about 1 ml of solution 
was placed on a gauze pad, which was applied to the target area of the skin, the 
distal leg (site of skin biopsy).  
Application of menthol, cinnamaldehyde and control substances 
A 3 x 3 cm gauze pad was placed on the distal leg 10 cm proximal to the lateral 
malleol for 20 min. In each of the 10 individuals, four gauze pads containing 
menthol, alcohol as control substance, cinnamaldehyde and acetone as control 
substance, respectively, were tested. The experiments were carried out in different 
days. 
Pain and thermal sensations 
The subjects were instructed to report any sensation of pain during the 20 min of 
gauze pad application. The pain was quantified by rating the intensity on a numeric 
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rating scale (NRS) 0-10, with 0 representing `no pain' and 10 being `the maximum 
pain that can be imagined'. 
The subjects and patients were instructed to report any sensation of pain during the 
20 min of gauze pad application. The pain was quantified by rating the intensity on a 
numeric rating scale (NRS 0±10, with 0 representing `no pain' and 10 being `the 
maximum pain that can be imagined'). 
Areas pinprick hyperalgesia were assessed using a von Frey filament with a flat tip 
(diameter 0.2mm). The area of hyperalgesia was determined along two orthogonal 
trajectories by testing pinprick sensitivity radially each 0.5cm from the centre in 
both directions. Dynamic mechanical allodynia was tested using a cotton wool swab 
perpendicular to the two trajectories. 
Thermal-Quantitative Sensory Testing (QST) battery 
Thermal sensation thresholds (warm, cold, heat and cold pain) were measured by a 
Quantitative sensory testing (Medoc TSAII, Israel) using a Peltier type thermode 
(probe 3x3cm) prior to and after menthol, alcohol, CA and acetone. The Peltier 
thermode was applied exactly in the area of gauze pad application. The method of 
limits was used by applying ramp stimuli with a velocity of 1°C/s starting from32°C 
(baseline temperature). The subjects were asked to press a button immediately the 
respective thermal sensation was perceived, or for painful sensation when the 
sensory sensation changed in painful sensation. The period between the 
achievement of the baseline temperature and the beginning of the following 
stimulus (inter-stimuli interval, ISI) was 0 s for warm and cold and 20 s for heat and 
cold pain detection thresholds. Thresholds were determined as the average of four 
successive stimuli. To protect the skin from injury, the increase of the thermode 
temperature was limited to 50°C, even if the button was not pressed. The limit for 
decreasing temperatures was 0°C. 
Skin biopsy. 
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In all patients and control healthy subjects included in the present study, skin 
biopsies were obtained from the proximal region of the thigh (20cm below the 
anterior iliac spine) and the distal region of the leg (10cm above the lateral 
malleolus). Biopsies were taken after local anaesthesia using a 3 mm disposable 
punch under sterile technique. Three sections randomly chosen from each biopsy 
were immunoassayed with polyclonal anti-protein-gene-product 9.5 antibodies 
(AbD serotec; 1:800) using the free-floating protocol for bright field 
immunohistochemistry previously described (Lauria et al., 2004). The linear density 
of IENF (IENF/mm) was calculated following the rules reported by the guidelines of 
the European Federation of the Neurological Societies (Lauria et al., 2010).  
Finally we quantified the dermal fiber density expressed as n°fiber per total dermal 
area [n/mm2]; the ratio from the area of dermal nervous structures and the total 
dermal area [Sp nerves (mm2)/Sp dermis (mm2)]. Then three sections from each 
biopsy were immunoassayed with monoclonal anti-myelin basic protein MBP (AbD 
serotec; 1:800, IgG2b isotype) and policlonal PGP9.5 using the free-floating protocol 
for double-indirect immunofluorecence histochemistry previously described (Lauria 
et al., 2004). We quantified the number of MBP-positive dermal bundles, and their 
length and area. The area of dermis and nerve bundles was measured on digitized 
images using SPOTTM advanced software. 
 
 
 
 
 
Results 
 
Patients and control clinical data at baseline are collected in table 1.  
Clinical findings 
Neuropathic pain dominated the clinical picture in all patients: eight C-SFN patients 
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and all ten of the B-SFN patients had spontaneous pain, all of them had evoked pain 
and only one C-SFN patient had evoked pain alone. Evoked pain was characterized 
by static light touch allodynia in four C-SFN patients and dynamic mechanic 
allodynia in two C-SFN patients. All C-SFN experienced cold hyperalgesia or cold 
allodynia at lower limb in a disco-proximal fashion.  In the B-SFN group, eight 
patients had both spontaneous and evoked pain, two patients had only spontaneous 
pain and none patient had evoked pain alone. We created the sensory profile (Fig 
1b) that summarizes the painful phenotype of B-SFN and C-SFN. 
Effects of L-menthol and cinnamaldehyde on pain and thermal sensations, thermal 
and sensory testing, mechanically evoked pain 
Pain and thermal sensation 
L-menthol induced significant cold sensations and no spontaneous pain in healthy 
subjects, while in seven B- SFN patients and in four C-SFN patients a spontaneous 
pain sensation has been reported.  
Five B- SFN patients described the pain as burning, one patient as sharp pain and 
one as icy-cold. The pain occurred with a latency of a few minutes and reached an 
intensity plateau of about NRS 6 after 7 min.  
While, only in four c-SFN patients L-menthol produced a spontaneous pain 
described as burning and pinprick sensation, with a latency of few seconds reaching 
a pick of about NRS 4 after 2 minutes then a decrease till NRS 0 after about three 
minutes, in five patients no sensation has been produced (Fig.3b).  
The pain induction was significant compared with alcohol placebo application that 
induced pain of a much lesser extent (NRS 2, for less then one minute) occasionally 
in only two healthy subjects and one B-SFN patients. 
CA produced a burning sensation in five of ten controls, in three of ten B-SFN and in 
two of C- SFN. All subjects who felt pain after CA described its quality as burning 
pain. The burning pain occurred with a latency of 7 min and reached a plateau after 
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9 min, with a mean NRS of 6 in healthy subjects and of 3 in B-SFN and C-SFN. In all 
subjects CA induced a warm sensation. Acetone induced a mild sensation of warm. 
Neither L-Menthol nor CA induced itching sensation. 
 
Skin flare 
L-menthol produced a visible skin flare in all control subjects and in same of the B-
SFN patients, with different area size (table 2). The L-menthol flare was significantly 
reduced or nearly abolished in the treated area in C-SFN patients (p<0.002). 
CA induced a presumably mild skin flare not reliably detectable withouth a laser 
Doppler or scan imager for skin blood flow quantification.    
Thermal testing 
L-Menthol and CA induced different changes in temperature detection thresholds 
and pain thresholds. Topical L-menthol induced in control cold hyperalgesia by a 
significant decrease in cold pain threshold, with a mean of 10°C of CP threshold. 
Further thermal thresholds were not affected by menthol or placebo. In C-SFN 
patients L-Menthol induced increase in WDT, while no difference in CS or CP 
phenomena were detected.  In B-SFN L-Menthol induced cold hyperalgesia in the 
flare area, while placebo induced in two patients decrease of heat pain threshold 
(44.2° prior; 43.5° after ethanol).  
CA induced cold hypoalgesia in six controls and in six B-SFN, while it produced heat 
allodynia in five controls and in 8 B-SFN (Fig. 6b).  
Mechanically evoked pain 
L-Menthol produced pinprick hyperalgesia in the flare area in healthy subjects and 
in 8 of 10 B-SFN patients, while in cold SFN no positive phenomena were detected.  
In C-SFN group CA induced tactile allodynia in two patients, pinprick hyperalgesia 
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four patients in the area of application and in the surrounding skin. CA produced 
pinprick hyperalgesia in six of ten controls and in six of ten B-SFN patients.  
 
 
Skin biopsy findings 
 
The IENF density was similar in C-SFN and B-SFN group (Table 1). The dermal 
innervation quantification shown a more severe denervation of dermal nerve 
bundles in c-SFN compared with burning SFN (table 2) and MBP-positive fibers were 
reduced compared with burning-SFN (Fig. 7b). 
 
 
 
 
 
 
 
 45
Table 1.  
 
 
Group 
 
 
C-SFN 
 
B-SFN 
 
S 
 
Control group 
 
S 
Patients (n, %) 9  10  10  
  Male (n, %) 6 5  5  
  Female (n, %) 4 5  5  
Age (years)* 54±7 57±12 ns 50±8 ns 
Height (cm)* 174±6 172±6 ns 175±5 ns 
BMI (kg/m2)* 26±2 28±1 ns 26±4 ns 
Clincal Evaluation  
Pinprick hypoesthesia 6 8 ns - ns 
Warm  
hypoesthesia 
3 8  -  
Cold 
hypoesthesia 
9 2  -  
Hyperalgesia 
 
4 5  -  
Static light touch allodynia 2 3 ns -  
Dynamic mechanic allodynia 2 3 ns -  
Warm  
Allodynia or hyperalgesia 
7 7 ns -  
Thermal QST  
CS P P  N  
CP P N  N  
WS P P  N  
HP N P  N  
IENF density  
(no/mm) * 
 
Distal leg 3.6±1.2 2.9±1.4 ns 8.4±2.1  
Proximal thigh 12.5±3.2 14.2±2.4 ns 26.3±4.6  
 
* mean±standard deviation; N= Normal; P=Pathological value. 
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Discussion 
 
We have demonstrated the presence of a peculiar cold pain phenotype in small fiber 
neuropathies. Cold pain dominates their clinical picture, that is described like a icy 
or glacial-cold, or a ongoing burning-cold or ongoing and evoked cold pain. Some 
patients reported the onset of pain about two years before the cold pain onset, with 
paresthesia or slight feeling of bandaging. In c-SFN clinical and QST evaluation 
showed a reduction of cold sensation and cold pain detection suggesting a low 
density cold-specific afferent fibers. Skin biopsy findings confirmed this hypothesis 
suggesting a more severe denervation of the dermis, related to a prominent 
reduction of myelinated MBP-positive dermal bundles, relatively preserved in b-SFN. 
In the present study we confirm for the hairy skin of distal leg the previous findings 
of L-Menthol and cinnamaldeyd application assessed in healthy subjects on the 
forearm, usually used in experimental pain (Wasner et al., 2004, Tugnoli et al., 
2007), or dorsal foot (Namer et al., 2005). In fact, we found in healthy subject after 
L-Menthol a strong cold sensation with several positive phenomena associated and 
after CA a slightly sensation of pungent pain or burning pain. Notably, L-Menthol 
application on distal leg induced poor or no cold sensory perception in c-SFN and 
the temporal sensation profile showed only in few patients a transient sensation of 
burning pain with onset after two minutes and a rapid decrease of the intensity of 
sensation into about three minutes (fig. 4b). In our opinion, it suggests an early 
receptor saturation related with low density TRPM8 receptors associated with 
presence of severe denervation. The placebo application confirm the specificity of L-
Menthol actions, and unlikely to previous studies we not found presence of 
significance changes after alcohol-placebo application (Namer et al., 2005), such as 
pinprick hyeralgesia or changes in warm sensation as a consequence of mild 
vasodilatation; the reason may refer to the different C-polimodal receptor 
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distribution between the forearm and the distal leg with larger receptive field in the 
lower limb.  
Previous studies described in different peripheral neuropathies the presence of two 
thermal threshold phenotypes: cold pain hyperalgesia without hypoaesthesia and 
cold pain hyperalgesia associated with cold hypoaesthesia (Verdugo and Ochoa, 
1992; Wasner et al., 2004; ). In our patients we found a similar cold painful pattern 
with presence of negative signs in the cold sensation pathway represented by cold 
mild or severe hypoaesthesia and cold pain hyperalgesia and pinprick hyperalgesia 
(Fig. 1b). We think it is related to cold sensitization of cold nociceptors (Verdugo and 
Ochoa, 1992). When we found a cold anaesthesia related with severe denervation 
only a ongoing spontaneous cold pain was reported, without cold hyperalgesia. 
TRPA1 in an interesting receptor with less clear function and more complex 
proprieties (Kwan et al., 2009). Recently a gain-of-function mutation in TRPA1 
(N855S) has been found in familial neuropathic pain syndrome characterized by 
episodic upper body pain triggered by fasting and physical stress, and punctate 
hyperalgesia at neurological evaluation (Kremeyer et al., 2010). 
As previously reported, topical application of CA induced burning sensation instead 
of the cold sensation (Prescott et al., 2000, Namer et al., 2005). CA induced 
sensation of slight burning with a high latency at the temporal sensation profile. 
In c-SFN group, CA induced sensation of slight burning suggesting a relatively 
integrity of C-fibers or TRPA-1 receptor afferents, however skin biopsy shown a 
severe dermal denervation and the intraepidermal fiber density was similarly 
denervated between c-SFN and b-SFN group (table 1). A central mechanisms can be 
suggested or another intriguing explanation may be the involvement in sensory 
TRPA1-mediated transduction of keratinocytes that express several TRP channels 
(TRPV3, TRPV4 and TRPA1) and may play a role in thermal transduction in 
physiological or pathological conditions (Schmelz et al., 2011).  
Concerning the burning SFN group we observed interesting findings. We choose a 
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well defined clinical pattern using extensive clinical evaluation, questionnaires, t-
QST and skin biopsy.  
SFN are often associated with burning ongoing pain in extremities and the 
characteristic clinical picture is usually well summarized with the expression of 
"burning feet syndrome". In previous studies patients with burning feet showed a 
heterogeneous sensory profile at sensory thresholds determination. Otherwise, in 
the present study we found in b-SFN group a distinct phenotype with almost 
stereotypical QST-pattern. Indeed, these patients had cold and warm hypoesthesia 
and severe warm hyperalgesia or allodynia at baseline evaluation. The reason may 
be in the extreme selection of patients because we choose only patients with 
isolated burning pain in order to compare a clear and representative clinical picture 
of burning pain, excluding patients that reported other sensory symptoms such as 
paraesthesia or sharp pain or cutting pain. The b-SFN group showed a peculiar 
pattern also after L-menthol and CA application. In particular CA induced more 
severe positive phenomena after warm stimuli, and we found almost in all patients 
warm allodynia. 
In conclusion, in the present study we showed a peculiar neuropathic phenotype of 
cold pain that could be explained by selective or predominant dysfunction of TRPM8 
receptor and A-delta thinly myelinated nerve fibers. Furthermore a selective group 
of patients with SFN complaining burning feet as exclusive painful syndrome shown 
a prevalent involvement of TRPA1 receptor afferent. More extensive studies are 
required to confirm these findings. 
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Figures 
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 Fig.1b. An example of sensory profile from a patient of the c-SFN group compared with a 
patient of the b-SFN group. 
 
A  
c-SFN*        b-SFN              Controls 
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B  
c-SFN*        b-SFN              Controls 
C  
c-SFN        b-SFN              Controls 
Fig. 2 b. Thermal thresholds (mean±SD) at baseline evaluation in c-SFN, b-SFN and control. 
*Indicates statistical significance p<0.05. At baseline, A) cold detection thresholds were higher in 
patients with cSFN, compared with the other groups; B) warm detection thresholds were higer in 
patients with b-SFN, compared with the others group and C) b-SFN group shown high variability in 
CPT, with positive phenomena like hyperalgesia or allodynia. 
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A     B 
Per visualizzare quest'immagine sono necessari QuickTime™ e un
decompressore 
.
 
Fig 3b.A. L-Menthol application at distal leg. B. Scheme of pinprick hyperalgesia and synamic 
mechanical allodynia detection, along two orthogonal trajectories each 0.5cm from the centre in 
both directions. See also the drawing of an example of the skin flare distribution after L-Menthol. 
 
 
 
 
 
Fig 4b. Time course of sensory rating to topical L menthol stimulation, values are given as mean 
ratings. In blue cold-SFN group, in red burning-SFN group and in green healthy control group. 
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Fig. 5b. Thermal thresholds (mean±SD) after L-Menthol or placebo (alcohol 70°).  
L-Menthol induced A) increase of the WDT in c-SFN compared with baseline or placebo; B) increase 
of cold pain thresholds in patients with b-SFN, compared with baseline or placebo. 
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Fig. 6b. Thermal thresholds (mean±SD) after Cinnamaldheid (CA) or placebo (acetone).  
CA induced in b-SFN A) decrease of the CPT compared with baseline or placebo with hyperalgesia 
or allodynia; B) decrease of the heat pain thresholds HPT thresholds compared with baseline or 
placebo. 
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Fig 7b. Skin biopsy taken in a cold-SFN patient and in a burning-SFN patient at the distal leg. 
Immunofluorecence staining study with anti-myelin-basic protein (MBP; AbD serotec). The density 
of MBP-positive dermal boundles are decreased in c-SFN compared with b-SFN.  
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Appendix A 
 
QUESTIONARIO ITALIANO PER IL DOLORE NEUROPATICO 
 
Data:  
Nome: ______________________  Cognome: ______________________________  
Sesso: M F 
Età: ______________________ 
Lei soffre di un dolore dovuto a un incidente o a una malattia del sistema nervoso. Questo dolore può  
essere di diversi tipi. Lei potrebbe provare un dolore spontaneo, ad esempio un dolore in assenza di  
qualsiasi stimolazione, che potrebbe essere continuo o manifestarsi sotto forma di brevi attacchi di  
dolore. Potrebbe anche provare un dolore provocato o accentuato dallo sfioramento, dalla pressione o dal contatto della 
parte dolorante con il freddo. Lei può provare uno o più tipi di dolore. Questo questionario è stato costruito per aiutare il 
suo medico a valutare e curare meglio i diversi tipi di dolore che prova.  
Vorremmo sapere se ha dolore spontaneo, cioè dolore in assenza di stimolazioni. Per ciascuna delle  
seguenti domande, la preghiamo di scegliere il numero che descrive meglio l’intensità media del dolore  
spontaneo che ha provato nelle ultime 24 ore. Scelga il numero 0 se non ha provato questo tipo di dolore (faccia un 
cerchietto attorno a un solo numero).  
 
Q1. Il dolore assomiglia a una sensazione di bruciore?  
 
Nessuna       0      1      2      3      4      5      6      7     8      9      10       La peggiore  
sensazione                                                                                             sensazione di bruciore  
di bruciore                                                                                             che si possa immaginare  
 
Q2. Il dolore assomiglia ad una stretta?  
 
Nessuna      0      1      2      3      4      5      6      7     8      9      10       La stretta più forte che  
stretta                                                                                                     si possa immaginare  
 
Q3. Il dolore assomiglia a una sensazione di compressione? 
  
Nessuna       0      1      2      3      4      5      6      7     8      9      10      La peggiore  
sensazione                                                                                             sensazione di compressione  
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di compressione                                                                                    che si possa immaginare  
Q4. Nelle ultime 24 ore, il dolore spontaneo è stato presente:  
Scelga la risposta che descrive meglio il suo caso.  
 
|__| In continuazione  
|__| Da 8 a 12 ore  
|__| Da 4 a 7 ore  
|__| Da 1 a 3 ore  
|__| Meno di 1 ora  
 
Vorremmo sapere se ha brevi attacchi di dolore. Per ciascuna delle seguenti domande, la preghiamo di scegliere il 
numero che descrive meglio l’intensità media dei suoi attacchi di dolore nelle ultime 24 ore. Scelga il numero 0 se non 
ha provato questo tipo di dolore (faccia un cerchietto attorno a un solo  
numero).  
 
      Q5. Il dolore è simile a delle scosse elettriche?  
 
Nessun       0      1      2      3      4      5      6      7     8      9      10         Il peggiore  
dolore simile                                                                                          dolore simile a  
a scosse elettriche                                                                                  scosse elettriche che si possa immaginare  
 
Q6. Il dolore è simile a una pugnalata?  
Nessun       0      1      2      3      4      5      6      7     8      9      10         Il peggiore  
dolore simile                                                                                          dolore simile a  
a una pugnalata                                                                                      una pugnalata che si possa  
                                                                                                               immaginare  
Q7. Nelle ultime 24 ore, quanti di questi attacchi di dolore ha avuto?  
Scelga la risposta che descrive meglio il suo caso.  
 
|__| Più di 20  
|__| Da 11 a 20  
|__| Da 6 a 10  
|__| Da 1 a 5  
|__| Nessun attacco di dolore  
 
Vorremmo sapere se avverte dolore provocato o accentuato dallo sfioramento, dalla pressione o dal contatto della 
parte dolorante con il freddo o con il caldo. Per ciascuna delle seguenti domande, la preghiamo di scegliere il numero 
che descrive meglio l’intensità media del dolore provocato nelle ultime 24 ore. Scelga il numero 0 se non ha provato 
questo tipo di dolore (faccia un cerchietto attorno a un solo numero).  
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Q8. Il dolore è provocato o accentuato dallo sfioramento della parte dolorante?  
Nessun       0      1      2      3      4      5      6      7     8      9      10         Il peggiore dolore  
dolore                                                                                                     che si possa immaginare  
 
Q9. Il suo dolore è provocato o accentuato dalla pressione sulla parte dolorante?  
 
Nessun       0      1      2      3      4      5      6      7     8      9      10         Il peggiore dolore  
dolore                                                                                                     che si possa immaginare  
 
Q10. Il dolore è provocato o accentuato dal contatto della parte dolorante con il freddo?  
 
Nessun       0      1      2     3      4      5      6      7     8      9      10         Il peggiore dolore  
dolore                                                                                                     che si possa immaginare  
 
Vorremmo sapere se ha delle sensazioni insolite nella parte dolorante. Per ciascuna delle seguenti  
domande, la preghiamo di scegliere il numero che descrive meglio l’intensità media delle sensazioni insolite nelle 
ultime 24 ore. Scelga il numero 0 se non ha avuto questo tipo di sensazione.  
 
Q11. Ha una sensazione di aghi o spilli?  
 
Nessuna       0      1      2      3      4      5      6      7     8      9      10       La peggiore  
sensazione                                                                                              sensazione di  
di aghi o spilli                                                                                         aghi o spilli che si possa  
                                                                                                          immaginare  
Q12. Avverte un formicolio?  
 
Nessun       0      1      2      3      4      5      6      7     8      9      10         Il peggiore formicolio  
formicolio                                                                                              che si possa immaginare  
 
